- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis SA (CLLS)
Cellectis SA stock price live, this page displays NASDAQ CLLS stock exchange data. View the CLLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectis SA real time stock price chart below.
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 4.750.
What Is the Stock Symbol for Cellectis SA?
The stock symbol for Cellectis SA is "CLLS."
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 4.750.
What Is the Stock Symbol for Cellectis SA?
The stock symbol for Cellectis SA is "CLLS."
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.670
4.871
52 wk Range
1.100
5.480
CLLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.6704.871
52 wk Range
1.1005.480
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
7.200
Upside
+51.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Cellectis SA Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Cellectis SA SWOT Analysis
Pipeline Progress | Cellectis advances key CAR T programs UCART22 and UCART20x22, with pivotal clinical data expected in 2025, potentially reshaping its market position |
Strategic Alliances | Explore Cellectis's collaborations with AstraZeneca, Servier, and Allogene, offering substantial milestone payments and expanding therapeutic reach |
Financial Outlook | With a cash runway into 2027 and Q3 2024 revenues exceeding $16 million, Cellectis maintains stability amid biotech sector volatility |
Analyst Projections | Price targets range from $4 to $6, reflecting optimism in Cellectis's gene therapy innovations and potential market disruption in cell therapies |
Cellectis SA Earnings Call Summary for Q3/2024
- Cash reserves increased to $264M, bolstered by $140M AstraZeneca investment and $47M collaboration funding
- Three new R&D programs initiated with AstraZeneca, including two allogeneic CAR T therapies and an in vivo gene therapy
- UCART123 program deprioritized; focus shifted to BALLI-01 study and other promising assets
- Company aims to extend cash runway to 2027 through financial management and partnership milestones
- Phase I data presentation planned for 2025; strong patient demand noted for UCART20x22 program
Last Updated: 11/07/2024, 03:10 AM
Read Full TranscriptCompare CLLS to Peers and Sector
Metrics to compare | CLLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.0x | −1.2x | −0.6x | |
PEG Ratio | −0.15 | 0.06 | 0.00 | |
Price/Book | 3.5x | 2.1x | 2.6x | |
Price / LTM Sales | 4.3x | 4.6x | 3.2x | |
Upside (Analyst Target) | 68.4% | 14.0% | 42.3% | |
Fair Value Upside | Unlock | 4.6% | 5.7% | Unlock |
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.200
(+51.58% Upside)
Earnings
Latest Release
Nov 07, 2025
EPS / Forecast
0.01 / -0.2338
Revenue / Forecast
37.16M / 8.52M
People Also Watch
FAQ
What Is the Cellectis (CLLS) Stock Price Today?
The Cellectis stock price today is 4.750
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is "CLLS."
What Is the Cellectis Market Cap?
As of today, Cellectis market cap is 352.06M.
What Is Cellectis's Earnings Per Share (TTM)?
The Cellectis EPS (TTM) is -0.35.
When Is the Next Cellectis Earnings Date?
Cellectis will release its next earnings report on Mar 10, 2026.
From a Technical Analysis Perspective, Is CLLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cellectis Stock Split?
Cellectis has split 0 times.
How Many Employees Does Cellectis Have?
Cellectis has 219 employees.
What is the current trading status of Cellectis (CLLS)?
As of Dec 27, 2025, Cellectis (CLLS) is trading at a price of 4.750, with a previous close of 4.840. The stock has fluctuated within a day range of 4.670 to 4.871, while its 52-week range spans from 1.100 to 5.480.
What Is Cellectis (CLLS) Price Target According to Analysts?
The average 12-month price target for Cellectis is USD7.2, with a high estimate of USD10 and a low estimate of USD4. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +51.58% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.